Article Text

PDF
Trials in rheumatoid arthritis: choosing the right outcome measures—comment on the article by Felson et al
  1. D Porter
  1. Gartnavel General Hospital, 1053 Great Western Rd, Glasgow, G12 0YN;
    Duncan.Porter@ggc.scot.nhs.uk
  1. D Porter, Gartnavel General Hospital, 1053 Great Western Rd, Glasgow, G12 0YN; Duncan

Statistics from Altmetric.com

Felson et al make a good case for choosing continuous, rather than dichotomous, variables as the primary outcome measures in randomised controlled trials in rheumatoid arthritis;1 however, outcome measures also need to be meaningful to the clinical community. In TICORA we chose two “co-primary” end-points: first, we employed the mean change in disease activity score (DAS) because this was the most sensitive outcome measure available at the time;2 we also used the achievement of a “good” response according to EULAR criteria because we believed that differences in response rates would be more readily understood. Interestingly, our understanding of the clinical relevance of the outcome measures has been borne out: …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.